TYRA News and Press, Tyra Biosciences Inc. From 03/29/23

Tyra Biosciences to Participate in Upcoming Investor Conferences PR Newswire CARLSBAD, Calif. , March 29, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medic...

2023-03-22 17:10:37 ET Tyra Biosciences press release ( NASDAQ: TYRA ): Q4 GAAP EPS of -$0.31 beats by $0.05 . Alan Fuhrman, CFO of TYRA, added, "TYRA is in a very strong financial position to begin 2023, with $251.2 million in cash and cash equivalents at year-end 202...

Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights PR Newswire -Initiated patient dosing with TYRA-300 in SURF301 oncology study- -Expanded pipeline beyond oncology into genetically defined conditions with TYRA-300 for achondrop...

2023-03-10 11:41:50 ET Gainers: Euda Health ( EUDA ) +53% . Unicycive ( UNCY ) +27% . Tenon Medical ( TNON ) +12% . Rain ( RAIN ) +11% . Altamira ( CYTO ) +11% . Losers: Meihua International ( MHUA ) -34% . Fr...

Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia PR Newswire - In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned t...

Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300 PR Newswire -TYRA-300 is the first oral, FGFR3-selective agent to be evaluated in the clinic- -Conference call and webcast today, Nov. 29th , at 9:00 am ET ...

Tyra Biosciences to Present at Upcoming Investor Conferences PR Newswire CARLSBAD, Calif. , Nov. 10, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor r...

Tyra Biosciences press release ( NASDAQ: TYRA ): Q3 GAAP EPS of -$0.30 beats by $0.11 . Third quarter 2022 net loss was $12.5 million compared to $6.6 million for the same period in 2021. Third quarter 2022 research and development expenses were $10.9 million compa...

Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights PR Newswire -Pipeline on track; SURF301 study to be initiated; IND for TYRA-200 to be filed by year-end 2022- -Well-capitalized with cash and cash equivalents of $263.2 million as ...

Tyra Biosciences Announces Planned Chief Financial Officer Transition PR Newswire - Esther van den Boom to transition to an advisor at year-end 2022- - Alan Fuhrman to be named Chief Financial Officer- CARLSBAD, Calif. , Nov. 2, 2022 ...